Secretion of Recombinant Interleukin-22 by Engineered Lactobacillus reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity.
Animals
Biomarkers
Diet
Disease Models, Animal
Fatty Liver
/ prevention & control
Interleukins
/ administration & dosage
Limosilactobacillus reuteri
/ genetics
Male
Metabolic Syndrome
/ therapy
Mice
Mice, Inbred C57BL
Obesity
/ etiology
Probiotics
/ therapeutic use
Recombinant Proteins
/ administration & dosage
Interleukin-22
IL-22
Lactobacillus reuteri
diet-induced metabolic syndrome
engineered probiotic
fatty liver disease
interleukin-22
nonalcoholic fatty liver disease
probiotic
steatosis
Journal
mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533
Informations de publication
Date de publication:
24 06 2020
24 06 2020
Historique:
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
16
7
2021
Statut:
epublish
Résumé
The incidence of metabolic syndrome continues to rise globally. In mice, intravenous administration of interleukin-22 (IL-22) ameliorates various disease phenotypes associated with diet-induced metabolic syndrome. In patients, oral treatment is favored over intravenous treatment, but methodologies to deliver IL-22 via the oral route are nonexistent. The goal of this study was to assess to what extent engineered
Identifiants
pubmed: 32581074
pii: 5/3/e00183-20
doi: 10.1128/mSphere.00183-20
pmc: PMC7316485
pii:
doi:
Substances chimiques
Biomarkers
0
Interleukins
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK101573
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK124696
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002373
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000427
Pays : United States
Informations de copyright
Copyright © 2020 Oh et al.
Références
Front Immunol. 2018 May 28;9:1155
pubmed: 29892294
Nucleic Acids Res. 2002 May 1;30(9):e36
pubmed: 11972351
Front Cell Dev Biol. 2019 Oct 22;7:235
pubmed: 31696115
J Bacteriol. 2018 Jun 11;200(13):
pubmed: 29686137
Rheumatology (Oxford). 2017 Mar 1;56(3):488-493
pubmed: 27940584
ACS Synth Biol. 2014 Feb 21;3(2):97-106
pubmed: 24932563
J Immunol. 1992 Feb 15;148(4):1176-81
pubmed: 1737934
Inflamm Res. 2014 Jul;63(7):519-25
pubmed: 24623532
PLoS One. 2012;7(2):e31951
pubmed: 22384111
Appl Environ Microbiol. 2019 May 2;85(10):
pubmed: 30683744
Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9
pubmed: 16716759
Front Bioeng Biotechnol. 2019 Jun 11;7:139
pubmed: 31245367
Nucleic Acids Res. 2014;42(17):e131
pubmed: 25074379
Infect Immun. 1998 Jul;66(7):3183-9
pubmed: 9632584
In Vivo. 2020 Jan-Feb;34(1):39-50
pubmed: 31882461
Saudi Pharm J. 2016 Jul;24(4):413-28
pubmed: 27330372
Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398
pubmed: 30902670
Gut. 2019 Aug;68(8):1504-1515
pubmed: 30448775
Biophys J. 2008 Mar 1;94(5):1754-65
pubmed: 18024507
Nature. 2014 Oct 9;514(7521):237-41
pubmed: 25119041
Circulation. 2004 Jan 27;109(3):433-8
pubmed: 14744958
J Pharmacol Pharmacother. 2014 Apr;5(2):83-7
pubmed: 24799810